ArticleScientific reports2025
Multicenter study on the distribution and prevalence of human papillomavirus types in Hangzhou, Zhejiang from 2017 to 2023.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Epidemiologic burden, clinical attribution, and implications for immunization strategies of HPV infection among males in Sichuan, China: a large-sample cross-sectional study.Virology journal · 2026Article
- Age distribution of high-risk HPV infection and cervical lesions in an unvaccinated adult Brazilian population within an organized screening program.Scientific reports · 2026Article
- Prevalence and genotype distribution of human papillomavirus in Sulaymaniyah, Kurdistan Region, Iraq.Frontiers in cellular and infection microbiology · 2026Article
- COVID-19 pandemic disruptions drive decreases in HPV prevalence and shift genotype distribution in Western China.BMC infectious diseases · 2025Article
- Towards HPV elimination: closing the gender gap by vaccinating and screening men.Lancet regional health. Americas · 2025Article
- Trends in the molecular epidemiology of human papillomavirus in males from the plateau region of Southwest China: an 11-year retrospective analysis (2014-2024).Virology journal · 2025Article
- Prevalence and type distribution of human papillomavirus in a Chinese urban population between 2019 and 2023: a retrospective study.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oncogenic human papillomavirus (HPV) infection is a major cause of anogenital cancers in both females and males. Nevertheless, only a limited number of studies have explored the epidemiology of HPV infection across genders within the same population. This retrospective study analyzed 299,089 samples from Hangzhou, China, collected between 2017 and 2023, including 283,556 females and 15,533 males. The overall HPV infection rate was 23.8%, with a prevalence of 22.85% in females and 41.13% in males. Gender differences were observed in the prevalence of high-risk HPV. In females, the most common high-risk HPV type was HPV52 (5.58%), followed by HPV58 (2.84%) and HPV16 (2.64%). In males, HPV52 (5.28%) was also the most prevalent, followed by HPV16 (5.08%) and HPV51 (3.57%). The age-related HPV infection rate shows a bimodal pattern, peaking in individuals under 20 years old and those aged 61-65. During the COVID-19 pandemic, the overall HPV infection rate declined by approximately 3% across all age groups. This study provides valuable insights into the dynamics of HPV infection in the context of the pandemic and emphasizes the need for HPV vaccination for adolescent males.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.